Arkayli Biopharma
Develops precision topical drug delivery systems for treatment of vascular anomalies, with a lead investigational topical esmolol gel intended to provide local treatment for infantile hemangioma while minimizing systemic exposure. Activities include formulation development, nonclinical safety assessment, clinical research coordination, regulatory strategy, and commercialization planning.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Investigational topical esmolol gel for infantile hemangioma
An investigational pediatric-specific topical gel formulation of esmolol designed for localized treatment of infantile hemangioma with minimal systemic exposure and once-daily application.
Investigational topical esmolol gel for infantile hemangioma
An investigational pediatric-specific topical gel formulation of esmolol designed for localized treatment of infantile hemangioma with minimal systemic exposure and once-daily application.
Services
Engagements for development partnerships and strategic collaborations to advance topical therapeutics for vascular anomalies.
Engagements for development partnerships and strategic collaborations to advance topical therapeutics for vascular anomalies.
Expertise Areas
- Topical drug delivery
- Pediatric formulation development
- Nonclinical toxicology and safety assessment
- Clinical trial design and multi-site study coordination
Key Technologies
- Topical gel formulation
- Local drug metabolism strategies
- Next-generation sequencing (NGS)
- Nonclinical toxicology studies
News & Updates
Selected as a winner in the Center for Advancing Innovation's Innovate Children’s Health Challenge.
Received state funding via a university-associated program to support development of a topical skin-based drug delivery system for hemangiomas.
Selected as a winner in the Center for Advancing Innovation's Innovate Children’s Health Challenge.
Received state funding via a university-associated program to support development of a topical skin-based drug delivery system for hemangiomas.